Vemurafenib-Induced Toxic Epidermal Necrolysis: An Emerging Adverse Event
Vemurafenib, a selective inhibitor of the BRAF V600 mutation, is Food and Drug Administration and European Medicines Agency approved for the treatment of stage IV metastatic melanoma alone or in combination. Among the adverse effects, cutaneous toxicity is the most common. Most of these reactions su...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Book |
| Published: |
Sociedade Portuguesa de Dermatologia e Venereologia,
2018-10-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Internet
Connect to this object online.3rd Floor Main Library
| Call Number: |
A1234.567 |
|---|---|
| Copy 1 | Available |